• Ascendis Pharma average return on tangible equity for 2024 was 284.7, a 96.04% decline from 2023.
• Ascendis Pharma average return on tangible equity for 2023 was 7186.9, a 9911.47% decline from 2022.
• Ascendis Pharma average return on tangible equity for 2022 was -73.25, a 41.16% decline from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.